12 JULY 2021
NEW NON-EXECUTIVE DIRECTOR ANNOUNCEMENT
We are pleased to announce that Bryn Roberts has been appointed to the Board as Non-Executive Director with effect from 1 August 2021.
17 JUNE 2021
DeepMatter collaborates with the Universities of Leeds and Sheffield
We are delighted to announce that we have been selected as a partner for the University of Leeds following a £1.4M EPSRC investment they received to develop automated precision manufacturing approaches in collaboration with the University of Sheffield, AstraZeneca, Somaserve and Samsung
7 April 2021
DeepMatter collaborates further with the University of Nottingham
DeepMatter is delighted to be collaborating again with the University of Nottingham’s School of Chemistry, providing access to the DigitalGlassware® platform to support the Universities’ sustainable chemistry initiatives.
11 MaRCH 2021
DeepMatter signs co-distribution agreement with Elemental Machines
DeepMatter is pleased to announce it has signed a co-distribution agreement with Elemental Machines, the US based organisation helping biotechnology and pharmaceutical companies identify research problems through its sensor-based products.
9 MaRCH 2021
DeepMatter is pleased to announce a DIRECTORATE CHANGE
DeepMatter is pleased to announce a new appointment to the Board, effective on 9 March 2021. Mirko Walter will join as a Non-Executive Director.
20 JANUARY 2021
DeepMatter subsidiary signs data licensing agreement with the Life Science business of Merck
DeepMatter subsidiary signs data licensing agreement with the Life Science business of Merck.
17 DECEMBER 2020
DeepMatter signs multi-year contract with Thieme Chemistry
DeepMatter announce that it has signed a three-year contract with Thieme Chemistry for the supply of technical data services and access to the Group’s proprietary algorithms.
19 OCTOBER 2020
Directorate Changes
Appointment of Non-Executive Chair and Chief Financial Officer
DeepMatter is pleased to announce two appointments to the Board, effective on 1 November 2020. Karen Bach will join as Non-Executive Chair and Fraser Benson will join as Chief Financial Officer.
16 OCTOBER 2020
STRONG ADOPTION
DEEPMATTER DOUBLES CUSTOMER NUMBERS FOR ITS MACHINE-LEARNING RETROSYNTHESIS TOOL
DeepMatter doubles customer numbers for its machine-learning retrosynthesis tool ICSYNTH.
4 JUNE 2020
DigitalGlassware™ to Interface with Waters' UNIFI Scientific Information System
DeepMatter announces plans to interface its DigitalGlassware™ platform with the Waters Corporation UNIFI™ Scientific Information System, enhancing the quality and accessibility of data for chemists worldwide.
14 APRIL 2020
DeepMatter's technology selected by Cancer Research UK Beatson Institute
DeepMatter announces collaboration with the Cancer Research UK Beatson Institute within its Drug Discovery Unit to enhance the reproducibility of its chemistry and accelerate drug discovery.
20 FEBRUARY 2020
DeepMatter collaborates with the University of Nottingham
DeepMatter is delighted to be collaborating with the University of Nottingham's School of Chemistry, to explore the benefits of the DigitalGlassware™ platform in data capture and analysis within undergraduate chemistry teaching.
12 FEBRUARY 2020
DeepMatter collaborates with the University of LeedS
DeepMatter and the Institute of Process Research and Development (iPRD) at the University of Leeds, have commenced a project to integrate DeepMatter's technology platform, DigitalGlassware™ within the iPRD's laboratories
9 DECEMBER 2019
DeepMatter announces collaboration
with AstraZeneca
DeepMatter announces collaboration with AstraZeneca focused on improving productivity of compound synthesis using digital technologies enabled with machine learning and artificial intelligence.
8 AUGUST 2019
O2H RELEASE - First revenues for DigitalGlassware™
Having parcipated in the Pioneer Programme, and being sufficiently impressed by the DigitalGlassware™ technology, o2h has elected to pay for the provision of a greater number of user licences. This roll out will enable o2h to use DigitalGlassware™ as part its drug-discovery collaboration with a strategic customer.